Benzinga · Aug 25, 2026
Bristol Myers Spokesperson Says Confirm That We Have Ended Our Partnership With Cellares; Determined Cellares-Partnered Cell Shuttle System Could Not Meet Necessary Requirements To Make Commercial Breyanzi
- Reuters
NYSE · BMY
Bristol-Myers Squibb Company
Healthcare · Drug Manufacturers - General
$66.58
Down-$0.37 (-0.55%)
Updated Aug 31, 2026, 5:24 AM
SID Score
7.5/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 104.23B
- P/E ratio
- 17.28
- Dividend yield
- 3.72%
- 52-week range
- $50.23 – $68.64
- Volume
- 5.54M
- Avg. volume
- 16.54M
Price performance
BMY price history
1M range · 20 trading sessions · Daily adjusted prices
BMY closed at $66.58 after 20 trading sessions, up 1.70% for the selected period.
- Last close
- $66.58
- Period change
- +1.70%
- Period low
- $63.61
- Period high
- $67.92
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $66.77 | $66.84 | $66.19 | $66.58 | 5.54M |
| Aug 27, 2026 | $66.59 | $67.47 | $66.20 | $66.95 | 4.67M |
| Aug 26, 2026 | $67.735 | $68.00 | $67.32 | $67.57 | 7.51M |
| Aug 25, 2026 | $66.42 | $68.05 | $66.42 | $67.92 | 7.91M |
| Aug 24, 2026 | $67.405 | $67.405 | $66.45 | $67.28 | 6.81M |
| Aug 21, 2026 | $65.79 | $67.55 | $65.13 | $67.01 | 6.84M |
| Aug 20, 2026 | $67.225 | $67.54 | $65.45 | $65.47 | 9.49M |
| Aug 19, 2026 | $66.80 | $68.64 | $66.61 | $67.61 | 13.89M |
| Aug 18, 2026 | $65.30 | $66.38 | $65.00 | $66.05 | 9.41M |
| Aug 17, 2026 | $63.60 | $64.74 | $63.36 | $64.63 | 7.29M |
| Aug 14, 2026 | $64.13 | $64.325 | $63.35 | $63.83 | 7.53M |
| Aug 13, 2026 | $64.05 | $65.02 | $63.91 | $64.65 | 10.53M |
| Aug 12, 2026 | $63.49 | $64.00 | $63.00 | $63.70 | 7.51M |
| Aug 11, 2026 | $64.56 | $65.02 | $63.54 | $63.61 | 9.37M |
| Aug 10, 2026 | $64.33 | $65.25 | $64.12 | $64.84 | 9.75M |
| Aug 7, 2026 | $64.24 | $64.73 | $63.7867 | $64.72 | 7.21M |
| Aug 6, 2026 | $64.90 | $64.94 | $63.20 | $64.15 | 9.55M |
| Aug 5, 2026 | $64.81 | $65.41 | $63.26 | $63.63 | 14.12M |
| Aug 4, 2026 | $64.89 | $66.31 | $63.8738 | $65.89 | 23.29M |
| Aug 3, 2026 | $66.12 | $68.10 | $64.14 | $65.47 | 32.97M |
Latest BMY news
The latest Smart Investors Daily articles mentioning BMY.
Stock researchCompany · Overview
BMY research
Overview
Company profile and research snapshot.
Company profile
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $53.25
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Argus Research | Buy | — |
| Aug 3, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jul 31, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 21, 2026
Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK
Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant in Houston, part of a larger $40 billion U.S. investment pledge. On the very same day, British regulators cleared Eli Lilly and Company (NYSE:LLY)’s […]
Yahoo · Aug 21, 2026
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?
BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.
Yahoo · Aug 21, 2026
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
